Department of Integrative Bioscience and Biotechnology, Institute of Anticancer Medicine Development, Sejong University, 209 Neungdong-ro, Gwangjin-gu, Seoul, 05006, Korea.
Department of Clinical Pharmacology and Therapeutics, Kyung Hee University School of Medicine, Seoul, 02447, Korea.
Stem Cell Res Ther. 2020 Jun 3;11(1):210. doi: 10.1186/s13287-020-01714-7.
The differentiation of human mesenchymal stem cells (hMSCs) into osteoblasts (OBs) is a prerequisite for bone formation. However, little is known about the definitive surface markers for OBs during osteogenesis.
To study the surface markers on OBs, we generated and used monoclonal antibodies (MAbs) against surface molecules on transforming growth factor-β1 (TGF-β1)-treated cancer cells. The generated MAbs were further selected toward expression changes on hMSCs cultured with TGF-β1/bone morphogenetic protein-2 (BMP-2) or osteogenic differentiation medium (ODM) by flow cytometry. Immunoprecipitation and mass spectrometry were performed to identify target antigens of selected MAbs. Expression changes of the target antigens were evaluated in hMSCs, human periodontal ligament cells (hPDLCs), and human dental pulp cells (hDPCs) during osteogenic and adipogenic differentiation by quantitative polymerase chain reaction (qPCR) and flow cytometry. hMSCs were also sorted by the MAbs using magnetic-activated cell sorting system, and osteogenic potential of sorted cells was evaluated via Alizarin Red S (ARS) staining and qPCR.
The binding reactivity of MR14-E5, one of the MAbs, was downregulated in hMSCs with ODM while the binding reactivity of ER7-A7, ER7-A8, and MR1-B1 MAbs was upregulated. Mass spectrometry and overexpression identified that MR14-E5, ER7-A7/ER7-A8, and MR1-B1 recognized integrin α2, α3, and αV, respectively. Upon osteogenic differentiation of hMSCs, the expression of integrin α2 was drastically downregulated, but the expression of integrin α3 and αV was upregulated in accordance with upregulation of osteogenic markers. Expression of integrin α3 and αV was also upregulated in hPDLCs and hDPCs during osteogenic differentiation. Cell sorting showed that integrin αV-high hMSCs have a greater osteogenic potential than integrin αV-low hMSCs upon the osteogenic differentiation of hMSCs. Cell sorting further revealed that the surface expression of integrin αV is more dramatically induced even in integrin αV-low hMSCs.
These findings suggest that integrin α3 and αV induction is a good indicator of OB differentiation. These findings also shed insight into the expression dynamics of integrins upon osteogenic differentiation of hMSCs and provide the reason why different integrin ligands are required for OB differentiation of hMSCs.
人类间充质干细胞(hMSCs)向成骨细胞(OBs)的分化是骨形成的前提。然而,人们对成骨过程中 OBs 的明确表面标志物知之甚少。
为了研究 OBs 的表面标志物,我们生成并使用了针对转化生长因子-β1(TGF-β1)处理的癌细胞表面分子的单克隆抗体(MAbs)。通过流式细胞术,进一步选择 hMSCs 用 TGF-β1/骨形态发生蛋白-2(BMP-2)或成骨分化培养基(ODM)培养时表达变化的 MAbs。通过免疫沉淀和质谱分析鉴定所选 MAbs 的靶抗原。通过定量聚合酶链反应(qPCR)和流式细胞术评估靶抗原在 hMSCs、人牙周韧带细胞(hPDLCs)和人牙髓细胞(hDPCs)成骨和成脂分化过程中的表达变化。通过磁激活细胞分选系统用 MAbs 对 hMSCs 进行分选,并通过茜素红 S(ARS)染色和 qPCR 评估分选细胞的成骨潜力。
MR14-E5 单抗之一的结合反应性在 hMSCs 用 ODM 培养时下调,而 ER7-A7、ER7-A8 和 MR1-B1 单抗的结合反应性上调。质谱分析和过表达鉴定出 MR14-E5、ER7-A7/ER7-A8 和 MR1-B1 分别识别整合素 α2、α3 和 αV。在 hMSCs 成骨分化过程中,整合素 α2 的表达急剧下调,而整合素 α3 和 αV 的表达上调,与成骨标志物的上调一致。在 hPDLCs 和 hDPCs 成骨分化过程中,整合素 α3 和 αV 的表达也上调。细胞分选显示,在 hMSCs 的成骨分化过程中,整合素 αV-高 hMSCs 的成骨潜力大于整合素 αV-低 hMSCs。细胞分选进一步表明,即使在整合素 αV-低 hMSCs 中,整合素 αV 的表面表达也更明显地被诱导。
这些发现表明整合素 α3 和 αV 的诱导是 OB 分化的良好指标。这些发现还深入了解了 hMSCs 成骨分化过程中整合素的表达动态,并提供了为什么 hMSCs 的 OB 分化需要不同的整合素配体的原因。